Deborah A Robins
5PUBLICATIONS
11CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|May 20, 2024
Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures.Raj Vuppalanchi, Rohit Loomba, Arun J Sanyal
|Sep 20, 2021
The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.Jonathan M Wilson, Yanzhu Lin, M Jane Luo
|Jan 19, 2021
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.Jonathan M Wilson, Amir Nikooienejad, Deborah A Robins
|Apr 16, 2020
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.Mark L Hartman, Arun J Sanyal, Rohit Loomba
|Jan 28, 2020
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.Juan Pablo Frias, Michael A Nauck, Joanna Van
Pageof 1
Frequent Collaborators
3 joint publications
Axel Haupt
2 joint publications
Mark L Hartman
2 joint publications
Giacomo Ruotolo
1 joint publications
Juan Pablo Frias
1 joint publications
Michael A Nauck
1 joint publications
Zvonko Milicevic
1 joint publications
Raj Vuppalanchi
1 joint publications
Rohit Loomba
1 joint publications
Arun J Sanyal
1 joint publications
Amir Nikooie
